Source:http://linkedlifedata.com/resource/pubmed/id/15461751
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2004-10-5
|
| pubmed:abstractText |
Despite aggressive intervention, cardiac causes of death, including acute coronary syndrome (ACS), continue to be a major source of mortality in patients with chronic kidney disease (CKD), including end-stage renal disease (ESRD). Multiple large prospective trials have demonstrated the clinical benefits of both low molecular weight heparin (LMWH) and glycoprotein (Gp) IIb/IIIa inhibitors in treating patients with ACS. Unfortunately patients with significant impairment of kidney function have generally been excluded from these major clinical trials. Consequently relatively little is known about the pharmacokinetics, appropriate dosing, efficacy, and safety of these medications in patients with CKD of various stages. This article examines the available literature regarding the pharmacokinetics, dosing, efficacy, and safety of LMWH and Gp IIb/IIIa inhibitors in patients with CKD.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0894-0959
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
17
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
411-5
|
| pubmed:dateRevised |
2005-11-16
|
| pubmed:meshHeading |
pubmed-meshheading:15461751-Aged,
pubmed-meshheading:15461751-Angina, Unstable,
pubmed-meshheading:15461751-Diabetes Mellitus, Type 2,
pubmed-meshheading:15461751-Diabetic Nephropathies,
pubmed-meshheading:15461751-Dose-Response Relationship, Drug,
pubmed-meshheading:15461751-Drug Administration Schedule,
pubmed-meshheading:15461751-Drug Therapy, Combination,
pubmed-meshheading:15461751-Follow-Up Studies,
pubmed-meshheading:15461751-Heparin, Low-Molecular-Weight,
pubmed-meshheading:15461751-Humans,
pubmed-meshheading:15461751-Kidney Failure, Chronic,
pubmed-meshheading:15461751-Male,
pubmed-meshheading:15461751-Platelet Aggregation Inhibitors,
pubmed-meshheading:15461751-Platelet Glycoprotein GPIIb-IIIa Complex,
pubmed-meshheading:15461751-Risk Assessment,
pubmed-meshheading:15461751-Treatment Outcome
|
| pubmed:articleTitle |
Use of low molecular weight heparins and glycoprotein IIb/IIIa inhibitors in patients with chronic kidney disease.
|
| pubmed:affiliation |
Renal, Electrolyte, and Hypertension Division, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.
|
| pubmed:publicationType |
Journal Article,
Review,
Case Reports
|